Magle Chemoswed Holding AB (publ) (STO: MAGLE)

Market Cap	629.35M
Revenue (ttm)	209.21M
Net Income (ttm)	16.75M
Shares Out	18.40M
EPS (ttm)	1.55
PE Ratio	22.06
Forward PE	16.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	953
Open	35.40
Previous Close	35.00
Day's Range	34.20 - 35.40
52-Week Range	23.60 - 49.80
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 78
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2023, MAGLE's revenue was 171.50 million, an increase of 15.89% compared to the previous year's 147.98 million. Earnings were 12.17 million, an increase of 33.07%.